LONDON - Johnson & Johnson’s booster dose of its vaccine was found to be 94% effective against symptomatic COVID-19 in the United States when administered two months after the first shot, the company announced on Tuesday.
The company shared new data from its late-stage clinical trial, which also showed that the J&J booster two months later was found to increase antibody levels four to six times higher than after just the single dose for adults ages 18 to 55.When given a J&J booster dose six months after the single shot, antibody levels "increased nine-fold one week after the booster and continued to climb to 12-fold higher four weeks after the booster" — regardless of age, the company said.The study's results have not yet been.